• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌:ESMO 共识会议指南 2012 年版。

Prostate cancer: ESMO Consensus Conference Guidelines 2012.

机构信息

Department of Radiotherapy, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK.

出版信息

Ann Oncol. 2013 May;24(5):1141-62. doi: 10.1093/annonc/mds624. Epub 2013 Jan 9.

DOI:10.1093/annonc/mds624
PMID:23303340
Abstract

The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological aspects. Before the conference, the expert panel prepared clinically relevant questions about prostate cancer in four areas for discussion as follows: diagnosis and staging, management of early localized disease, management of advanced localized disease and systemic disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update.

摘要

2011 年 11 月 17 日至 19 日,第一届欧洲肿瘤内科学会前列腺癌共识会议在瑞士苏黎世举行,由包括方法学方面专家在内的多学科专业小组参加。会议前,专家组就前列腺癌的四个领域准备了与临床相关的问题,供以下四个方面讨论:诊断和分期、早期局限性疾病的治疗、局限性晚期疾病的治疗和全身疾病的治疗。专家组事先审查了所有相关的科学文献。在共识会议期间,专家组为每个具体问题制定了建议。这里详细介绍的建议是在仔细审查已发表数据的基础上达成的专家共识。所有与会者都批准了这一最终更新。

相似文献

1
Prostate cancer: ESMO Consensus Conference Guidelines 2012.前列腺癌:ESMO 共识会议指南 2012 年版。
Ann Oncol. 2013 May;24(5):1141-62. doi: 10.1093/annonc/mds624. Epub 2013 Jan 9.
2
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.1 届 ESMO 肺癌共识会议;卢加诺 2010 年:小细胞肺癌。
Ann Oncol. 2011 Sep;22(9):1973-1980. doi: 10.1093/annonc/mdr313. Epub 2011 Jul 4.
3
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.转移性非小细胞肺癌:病理和分子检测共识,一线、二线和三线治疗:1 次 ESMO 肺癌共识会议;2010 年卢加诺。
Ann Oncol. 2011 Jul;22(7):1507-1519. doi: 10.1093/annonc/mdr150. Epub 2011 May 2.
4
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.晚期前列腺癌患者的管理:2019年晚期前列腺癌共识会议报告
Eur Urol. 2020 Apr;77(4):508-547. doi: 10.1016/j.eururo.2020.01.012. Epub 2020 Jan 27.
5
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.晚期前列腺癌患者的管理。第一部分:中高危和局部进展性疾病、生化复发和激素治疗的副作用:2022 年晚期前列腺癌共识会议报告。
Eur Urol. 2023 Mar;83(3):267-293. doi: 10.1016/j.eururo.2022.11.002. Epub 2022 Dec 6.
6
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.ESMO-ESGO-ESTRO 子宫内膜癌共识会议:诊断、治疗和随访。
Ann Oncol. 2016 Jan;27(1):16-41. doi: 10.1093/annonc/mdv484. Epub 2015 Dec 2.
7
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.欧洲肿瘤内科学会(ESMO)-欧洲妇科肿瘤学会(ESGO)-欧洲放射肿瘤学会(ESTRO)子宫内膜癌共识会议:诊断、治疗与随访
Radiother Oncol. 2015 Dec;117(3):559-81. doi: 10.1016/j.radonc.2015.11.013. Epub 2015 Dec 9.
8
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.欧洲肿瘤内科学会-欧洲妇科肿瘤学会-欧洲放射肿瘤学会子宫内膜癌共识会议:诊断、治疗与随访
Int J Gynecol Cancer. 2016 Jan;26(1):2-30. doi: 10.1097/IGC.0000000000000609.
9
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.晚期前列腺癌-转移性和/或去势抵抗性前列腺癌患者的管理:2022 年晚期前列腺癌共识会议(APCCC)报告。
Eur J Cancer. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3.
10
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.欧洲肿瘤内科学会(ESMO)-欧洲妇科肿瘤学会(ESGO)关于卵巢癌的共识会议建议:病理学与分子生物学、早期和晚期阶段、交界性肿瘤及复发性疾病
Int J Gynecol Cancer. 2019 May 7;29(4):728-760. doi: 10.1136/ijgc-2019-000308.

引用本文的文献

1
Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center.转移性去势抵抗性前列腺癌且体能状态下降男性患者使用新型激素药物:一家专业单中心的经验
Aging Med (Milton). 2024 Dec 19;7(6):761-769. doi: 10.1002/agm2.12372. eCollection 2024 Dec.
2
Criteria and indicators to evaluate quality of care in genitourinary tumour boards.评价泌尿生殖系统肿瘤委员会医疗质量的标准和指标。
Clin Transl Oncol. 2024 Jul;26(7):1639-1646. doi: 10.1007/s12094-024-03381-z. Epub 2024 Feb 11.
3
Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems.
前列腺癌放射治疗的再设计:全民医疗保健系统的建议。
J Comp Eff Res. 2023 Dec;12(12):e230023. doi: 10.57264/cer-2023-0023. Epub 2023 Nov 2.
4
Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia.用于前列腺癌的雄激素剥夺疗法影响身体成分,增加了发生肌肉减少症的风险。
Nutrients. 2023 Mar 28;15(7):1631. doi: 10.3390/nu15071631.
5
Experience of bipolar androgen therapy (BAT) in Argentinian oncology centres.阿根廷肿瘤中心的双相雄激素疗法(BAT)经验。
Ecancermedicalscience. 2022 Dec 2;16:1480. doi: 10.3332/ecancer.2022.1480. eCollection 2022.
6
Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.百万退伍军人计划中任何、转移和致命前列腺癌的多基因风险。
J Natl Cancer Inst. 2023 Feb 8;115(2):190-199. doi: 10.1093/jnci/djac199.
7
The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.已确定的前列腺癌中与趋化因子相关的预后基因特征:对雄激素拮抗剂和免疫治疗的影响。
Front Immunol. 2022 Oct 6;13:1009634. doi: 10.3389/fimmu.2022.1009634. eCollection 2022.
8
High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice.肿瘤内高浓度双氢睾酮与去势小鼠中VCaP前列腺癌异种移植瘤的抗雄激素耐药相关。
iScience. 2022 Apr 25;25(5):104287. doi: 10.1016/j.isci.2022.104287. eCollection 2022 May 20.
9
Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.建立一个与年龄和肿瘤微环境相关的基因特征,用于预测前列腺癌的生存情况。
Cancer Med. 2022 Nov;11(22):4374-4388. doi: 10.1002/cam4.4776. Epub 2022 May 9.
10
Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations.转移性去势抵抗性前列腺癌患者根据体细胞损伤 DNA 修复基因改变的结果。
Curr Oncol. 2022 Apr 15;29(4):2776-2791. doi: 10.3390/curroncol29040226.